Depression trials

Venlafaxine extended release, in doses of 75 to 225 mg/day, improves social anxiety, performance, and avoidance behavior with a reduction in disability.61 Treatment with venlafaxine results in response rates similar to those seen with paroxetine.60 Venlafaxine may be effective in SSRI non-responders.62 As with SSRIs, doses should be tapered slowly when discontinuing therapy. Tolerability is similar to that observed in depression trials with venlafaxine extended release. Common side effects are anorexia, dry mouth, nausea, insomnia, and sexual dysfunction. 

Arif Khan, Nick Redding and Walter A. Brown, 2008. Hypericum Depression Trial Study Group, 2002. 

Hudson, Christopher G., Socioeconomic Status and Mental Illness Tests of the Social Causation and Selection Hypotheses , American Journal of Orthopsychiatry 75, no. 1 (2005) 3-18 The Humble Humbug , The Lancet 2 (1954) 321 Hunter, Aimee M., Andrew F. Leuchter, Melinda L. Morgan and Ian A. Cook, Changes in Brain Function (Quantitative EEG Cordance) During Placebo Lead-in and Treatment Outcomes in Clinical Trials for Major Depression , American Journal of Psychiatry 163, no. 8 (2006) 1426-32 Hyland, Michael E., Do Person Variables Exist in Different Ways , American Psychologist 40 (1985) 1003-10 Hypericum Depression Trial Study Group, Effect of Hypericum Perforatum (St John s Wort) in Major Depressive Disorder A Randomized Controlled Trial , Journal of the American Medical Association 287 (2002) 1807-14... 

Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John s wort) in major depresssive disorder. J. Am. Med. Assoc. 287, 1807-1814. 2002. 

A number of studies have suggested St. John s wort as a viable treatment for depression. In one study of more than 3,000 patients with mild to moderate depression, over three quarters showed improvement after four weeks of using the herb. In another study, patients who received St. John s wort showed significantly more improvement than patients who received a placebo. Although St. John s wort may provide benefits to individuals with milder forms of depression (Lawvere Mahoney, 2005), recent studies have indicated that it is not effective in the treatment of major depression (Hypericum Depression Trial Study Group, 2002 Shelton et al., 2001). 

Patients treated with paroxetine or sertraline showed improvement in anxiety and avoidance symptoms and a decrease in disability. Daily doses up to 60 mg of paroxetine and 200 mg of sertraline were well tolerated, and emergent adverse effects were similar to those of depression trials (e.g., nausea, sexual dysfunction, sweating, and somnolence). The onset of effect was delayed 4 to 8 weeks, and maximum benefit was often not observed until 12 weeks or longer. Sertraline is also effective in disabled patients suffering from the marked to severe form of generalized SAD. Limited data suggest that citalopram, escitalopram, and fluvoxamine are also effective in treating SAD. Fluoxetine was not effective in SAD. ... 

Most studies concern patients with soendogenous depression. Trials with patients with various types of depression in one group may also impose limitations on the value of the results. 

No) Name Formulae Type of Depression Trial Mechanism References [I... 

---